Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook > Product Catalogue >API >Inhibitors >Brigatinib

Brigatinib

Brigatinib Structure
  • ₹0
  • Product name: Brigatinib
  • CAS: 1197953-54-0
  • MF: C29H39ClN7O2P
  • MW: 584.09
  • EINECS:1592732-453-0
  • MDL Number:
  • Synonyms:Brigatinib;Brigatinib, AP26113;5-Chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-2,4-pyrimidinediamine;atinib;Bri atinib ;2,4-Pyrimidinediamine, 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-;Brigatinib USP/EP/BP;1197953-54-0 Brigatinib
Manufacturer Product number Product description Packaging Price Updated Buy

Properties

Melting point :>203°C (dec.)
Boiling point :781.8±70.0 °C(Predicted)
Density :1.31±0.1 g/cm3(Predicted)
storage temp. :-20°C
solubility :Soluble in DMSO (1 mg/ml with warming)
form :solid
pka :8.14±0.42(Predicted)
color :White to off-white
Stability :Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
InChIKey :AILRADAXUVEEIR-UHFFFAOYSA-N
SMILES :C1(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C=C2OC)=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1
CAS DataBase Reference :1197953-54-0

Safety Information

Symbol(GHS): GHS hazard pictograms
Signal word: Warning
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H302 Harmful if swallowed Acute toxicity,oral Category 4 Warning GHS hazard pictograms P264, P270, P301+P312, P330, P501
H315 Causes skin irritation Skin corrosion/irritation Category 2 Warning GHS hazard pictograms P264, P280, P302+P352, P321,P332+P313, P362
H319 Causes serious eye irritation Serious eye damage/eye irritation Category 2A Warning GHS hazard pictograms P264, P280, P305+P351+P338,P337+P313P
H335 May cause respiratory irritation Specific target organ toxicity, single exposure;Respiratory tract irritation Category 3 Warning GHS hazard pictograms
Precautionary statements:
P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

Description

Brigatinib is a small molecule inhibitor of both ALK and EGFR [195]. In preclinical models, “triple-mutant EGFR”-positive cells (activating EGFR mutation/ T790M/C797S) responded to the combination of brigatinib with an anti-EGFR monoclonal antibody, cetuximab or panitumumab [196]. Single-agent activity of brigatinib in a phase I/II trial was only 5% [197], possibly compounded by low plasma concentrations [196], but the addition of an anti-EGFR monoclonal antibody remains to be clinically tested. The preclinical data with brigatinib and EAI045?in laboratory models with a C797S mutation demonstrate that combination therapies with an anti-EGFR monoclonal antibody may lead to overcoming resistance to osimertinib.

Related product price